Obstructive NSTE-ACS clinical trials at University of California Health
1 research study open to eligible people
Infrasensor for Early Detection of a High-grade Obstructive NSTE-ACS
open to eligible people ages 18 years and up
The objective of this prospective, cross-sectional, multicenter pivotal trial study is to validate Infrasensor's clinical performance for the detection of high grade obstructive NSTE-ACS. High-grade obstructive NSTE-ACS is defined as an acute coronary syndrome in which severe obstructive coronary artery disease, including total coronary artery occlusion is present. Study Endpoints Primary Endpoint: Infrasensor performance (Lower bound of 95% CI for sensitivity, specificity) between device detection of high-grade obstructive NSTE-ACS and angiographic diagnosis of High-grade obstructive CAD defined as the aggregate of >50% left main stenosis, or >70% stenosis in 1 or more coronary arteries and/or emergent revascularization. Secondary Endpoint: Infrasensor performance (positive and negative predictive values, and overall accuracy).
at UCSD UCSF
Our lead scientists for Obstructive NSTE-ACS research studies include Alan Wu, Ph.D.
Last updated: